Investigating how low-level arsenic exposure affects diabetes in American Indian communities.
The Epitranscriptome as a Novel Mechanism of Arsenic-Induced Diabetes.
This study is looking at how small amounts of arsenic might affect diabetes in American Indian communities by exploring changes in RNA, which could help us understand how to better prevent and treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11100902 on NIH RePORTER |
What this research studies
This research focuses on understanding the relationship between low-level arsenic exposure and diabetes, specifically in American Indian populations. By examining the N6-methyladenosine (m6A) epitranscriptome, the study aims to uncover how changes in RNA modifications may contribute to diabetes development. Utilizing advanced sequencing technologies, researchers will analyze RNA samples to gain insights into the molecular mechanisms at play. This approach allows for a more precise understanding of how arsenic impacts health, potentially leading to targeted interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research are American Indian individuals aged 21 and older who may have been exposed to low levels of arsenic.
Not a fit: Patients who do not belong to the American Indian community or who have not been exposed to arsenic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing and managing diabetes in populations exposed to arsenic.
How similar studies have performed: Previous research has shown promising results in understanding the role of epitranscriptomics in disease mechanisms, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Navas-Acien, Ana — Columbia University Health Sciences
- Study coordinator: Navas-Acien, Ana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.